

CORRECTION

Open Access



Correction: Xuebijing as a potential therapeutic option for septic shock: the need for rigorous evaluation of life-threatening adverse effects

Patrick M. Honoré^{1*}, Ilann Oueslati², Catherine Yildiz Muscato³, Sarah Dahma³, Sydney Blackman² and Nathan De Lissnyder⁴

Correction: *Critical Care* (2025) 29:522
<https://doi.org/10.1186/s13054-025-05798-6>

Following publication of the original article [1], the authors identified an error in the citation of *Reference 2*. The initially cited *Reference 2* was incorrectly interpreted and does not appropriately support the statement for which it was cited. Accordingly, the former *Reference 2* has been replaced with a more appropriate citation (now *Reference 2*) [3], which accurately supports the statement.

In the original version of the manuscript, the following sentence cited the former *Reference 2*: “A recent review of XBJ in sepsis-associated acute kidney injury identified two documented cases of immediate, life-threatening anaphylactic shock following intravenous injection in septic patients [2].”

This statement has been corrected to more accurately reflect the data reported in the new *Reference 2*: “A recent review of XBJ involving 81 cases with reported adverse drug reactions identified five documented cases of immediate, life-threatening anaphylactic shock following intravenous injection in patients [3].”

The reason for this change is that the former *Reference 2* discussed the safety profile of Xuebijing but did not report cases of anaphylaxis. In contrast, the new *Reference 2* clearly describes five documented cases of immediate, life-threatening anaphylactic shock following intravenous injection in patients.

The correct reference is indicated in this correction article and the original article [1] has been corrected.

Published online: 03 April 2026

Reference

1. Honoré PM, Oueslati I, Muscato CY, Dahma S, Blackman S, De Lissnyder N. Xuebijing as a potential therapeutic option for septic shock: the need for rigorous evaluation of life-threatening adverse effects. *Crit Care*. 2025;29(1):522. <https://doi.org/10.1186/s13054-025-05798-6>. PMID: 41373031; PMCID: PMC12696941.
2. Shu B, Zhou X, Fan J, Yang C, Deng W, Fang B, Zhang H. Comparative efficacy and safety of Xuebijing injection as adjuvant therapy in sepsis-associated acute kidney injury: a systematic review and meta-analysis. *Front Pharmacol*. 2025;16:1643557. <https://doi.org/10.3389/fphar.2025.1643557>. PMID: 41194878; PMCID: PMC12583064.

The original article can be found online at <https://doi.org/10.1186/s13054-025-05798-6>.

*Correspondence:

Patrick M. Honoré
patrick.honore@chuclnhamur.uclouvain.be

¹CHU UCL Godinne Namur, UCLouvain Medical School, Campus Godinne Avenue G Thérasse 1, Yvoir 5530, Belgium

²ULB University, Brussels, Belgium

³Medical Student, Faculty of Medicine, ULB University, Brussels, Belgium

⁴Universiteit Brussel, Brussels, Belgium



© The Author(s) 2026. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

3. He F, Chen H, Zhang X, He S, Li J, Dong W. Study on ADR Centralized Monitoring of Xuebijing Injection in Our Hospital. *China Pharmacy* 2017(12): 4089-4092- Article em Zh | WPRIM | ID: wpr-658573.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.